Montelukast: The New Therapeutic Option for the Treatment of Epilepsy

References

• Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689–701. doi:10.1016/S0140-6736(18)32596-0
   PubMed Web of Science ®Google Scholar
• Brueggeman L, Sturgeon ML, Martin RM, et al. Drug repositioning in epilepsy reveals novel antiseizure candidates. Ann Clin Transl Neurol. 2019;6(2):295–309. doi:10.1002/acn3.703
   Web of Science ®Google Scholar
• Guberman A. Vagus nerve stimulation in the treatment of epilepsy. Cmaj. 2004;171(10):1165–1166. doi:10.1503/cmaj.1041039
   Web of Science ®Google Scholar
• D’Ambrosio R, Eastman CL, Fattore C, Perucca E. Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. Expert Rev Neurother. 2013;13(6):615–625. doi:10.1586/ern.13.54
   PubMed Web of Science ®Google Scholar
• Ventola CL. Epilepsy management: newer agents, unmet needs, and future treatment strategies. Pharm Ther. 2014;39(11):776.
   Google Scholar
• Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. In: Handbook of Clinical Neurology. Vol. 119. Elsevier; 2014:417–432.
   Google Scholar
• Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals. 2010;3(7):2090–2110. doi:10.3390/ph3072090
   Google Scholar
• Zhou L, Sun X, Shi Y, Liu J, Luan G, Yang Y. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood–brain barrier. Inflammopharmacology. 2019;27(5):933–940. doi:10.1007/s10787-019-00611-7
   Web of Science ®Google Scholar
• Scholz BH. Neuropsychiatric disorder and montelukast: a case report and vigibase® analysis. Arch Dis Child. 2019;104(1):54–55.
   Google Scholar
• Lai J, Mei ZL, Wang H, et al. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling. Neurochem Int. 2014;75(May):26–31. doi:10.1016/j.neuint.2014.05.006
   Web of Science ®Google Scholar
• Hoxha M, Lewis-Mikhael A-M, Bueno-Cavanillas A. Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: a systematic review of human clinical trials and in vivo animal studies. Biomed Pharmacother. 2018;106:956–965. doi:10.1016/j.biopha.2018.07.033
   Web of Science ®Google Scholar
• Fleck J, Temp FR, Marafiga JR, et al. Montelukast reduces seizures in pentylenetetrazol-kindled mice. Brazilian J Med Biol Res. 2016;49(4):1–7. doi:10.1590/1414-431X20155031
   Web of Science ®Google Scholar
• Cevik B, Solmaz V, Aksoy D, Erbas O. Montelukast inhibits pentylenetetrazol-induced seizures in rats. Med Sci Monit. 2015;21:869–874. doi:10.12659/MSM.892932
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181. doi:10.1038/nrc2809
   PubMed Web of Science ®Google Scholar
• Ghosh A, Chen F, Thakur A, Hong H. Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders. CNS Neurosci Ther. 2016;22(12):943–951. doi:10.1111/cns.12596
   PubMed Web of Science ®Google Scholar
• Izumi T, Yokomizo T, Obinata H, Ogasawara H, Shimizu T. Leukotriene receptors: classification, gene expression, and signal transduction. J Biochem. 2002;132(1):1–6. doi:10.1093/oxfordjournals.jbchem.a003185
   Web of Science ®Google Scholar
• Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A. Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med. 2010;12(2):133–148. doi:10.1007/s12017-009-8092-z
   PubMed Web of Science ®Google Scholar
• Rahman SO, Singh RK, Hussain S, Akhtar M, Najmi AK. A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer’s disease. Eur J Pharmacol. 2019;842:208–220. doi:10.1016/j.ejphar.2018.10.040
   Web of Science ®Google Scholar
• Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L. Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases. Mediators Inflamm. 2017;2017:1–15. doi:10.1155/2017/3454212
   Web of Science ®Google Scholar
• Williamson JR, Cooper RH, Joseph SK, Thomas AP. Inositol trisphosphate and diacylglycerol as intracellular second messengers in liver. Am J Physiol Physiol. 1985;248(3):C203–C216. doi:10.1152/ajpcell.1985.248.3.C203
   Web of Science ®Google Scholar
• Rehni AK, Singh TG. Modulation of leukotriene D4 attenuates the development of seizures in mice. Prostaglandins Leukot Essent Fat Acids. 2011;85(2):97–106. doi:10.1016/j.plefa.2011.04.003
   Web of Science ®Google Scholar
• Savari S, Vinnakota K, Zhang Y, Sjölander A. Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. World J Gastroenterol. 2014;20(4):968. doi:10.3748/wjg.v20.i4.968
   Web of Science ®Google Scholar
• Kawai Y, Narita Y, Yamawaki-Ogata A, Usui A, Komori K. Montelukast, a cysteinyl leukotriene receptor 1 antagonist, induces m2 macrophage polarization and inhibits murine aortic aneurysm formation. Biomed Res Int. 2019;2019:1–11. doi:10.1155/2019/9104680
   Web of Science ®Google Scholar
• Yokomizo T, Nakamura M, Shimizu T. Leukotriene receptors as potential therapeutic targets. J Clin Invest. 2018;128(7):2691–2701. doi:10.1172/JCI97946
   PubMed Web of Science ®Google Scholar
• Kaya Z, Yayla M, Cinar I, et al. Effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, on a rat model of acute bacterial sinonasal inflammation. Am J Rhinol Allergy. 2019;33(5):559–566. doi:10.1177/1945892419852576
   Web of Science ®Google Scholar
• Dupré DJ, Le Gouill C, Gingras D, Rola-Pleszczynski M, Staňková J. Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1. J Pharmacol Exp Ther. 2004;309(1):102–108. doi:10.1124/jpet.103.059824
   Web of Science ®Google Scholar
• Laidlaw TM, Boyce JA. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy. 2012;42(9):1313–1320. doi:10.1111/j.1365-2222.2012.03982.x
   PubMed Web of Science ®Google Scholar
• Ciccarelli R, D’Alimonte I, Santavenere C, et al. Cysteinyl‐leukotrienes are released from astrocytes and increase astrocyte proliferation and glial fibrillary acidic protein via cys‐LT1 receptors and mitogen‐activated protein kinase pathway. Eur J Neurosci. 2004;20(6):1514–1524. doi:10.1111/j.1460-9568.2004.03613.x
   Web of Science ®Google Scholar
• Robel S. Astroglial scarring and seizures: a cell biological perspective on epilepsy. Neurosci. 2017;23(2):152–168.
   Google Scholar
• Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: beyond the neuron. Front Cell Neurosci. 2018;12:72.
   PubMed Web of Science ®Google Scholar
• Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31. doi:10.1038/nrneurol.2010.178
   PubMed Web of Science ®Google Scholar
• Sharma R, Leung WL, Zamani A, O’brien TJ, Espinosa PMC, Semple BD. Neuroinflammation in post-traumatic epilepsy: pathophysiology and tractable therapeutic targets. Brain Sci. 2019;9(11):318. doi:10.3390/brainsci9110318
   Web of Science ®Google Scholar
• Lucas S, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147(S1):S232–S240. doi:10.1038/sj.bjp.0706400
   PubMed Web of Science ®Google Scholar
• Lenz QF, Arroyo DS, Temp FR, et al. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood–brain barrier dysfunction. Neuroscience. 2014;277:859–871. doi:10.1016/j.neuroscience.2014.07.058
   PubMed Web of Science ®Google Scholar
• Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology. 2013;69:16–24. doi:10.1016/j.neuropharm.2012.04.004
   PubMed Web of Science ®Google Scholar
• Mansour RM, Ahmed MAE, El-Sahar AE, El Sayed NS. Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: possible role of its antioxidant, anti-inflammatory and antiapoptotic effects. Toxicol Appl Pharmacol. 2018;358(September):76–85. doi:10.1016/j.taap.2018.09.012
   Web of Science ®Google Scholar
• Sperk G, Lassmann H, Baran H, Kish SJ, Seitelberger F, Hornykiewicz O. Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience. 1983;10(4):1301–1315. doi:10.1016/0306-4522(83)90113-6
   Web of Science ®Google Scholar
• Michael J, Marschallinger J, Aigner L. The leukotriene signaling pathway: a druggable target in Alzheimer’s disease. Drug Discov Today. 2019;24(2):505–516. doi:10.1016/j.drudis.2018.09.008
   Web of Science ®Google Scholar
• Farias S, Frey LC, Murphy RC, Heidenreich KA. Injury-related production of cysteinyl leukotrienes contributes to brain damage following experimental traumatic brain injury. J Neurotrauma. 2009;26(11):1977–1986. doi:10.1089/neu.2009.0877
   Web of Science ®Google Scholar
• Palmer MR, Mathews WR, Hoffer BJ, Murphy RC. Electrophysiological response of cerebellar Purkinje neurons to leukotriene D4 and B4. J Pharmacol Exp Ther. 1981;219(1):91–96.
   Web of Science ®Google Scholar
• Van Vliet EA, Otte WM, Wadman WJ, et al. Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats I: magnetic resonance imaging. Epilepsia. 2016;57(1):59–69. doi:10.1111/epi.13246
   Web of Science ®Google Scholar
• Rempe RG, Hartz AMS, Soldner ELB, et al. Matrix metalloproteinase-mediated blood-brain barrier dysfunction in epilepsy. J Neurosci. 2018;38(18):4301–4315. doi:10.1523/JNEUROSCI.2751-17.2018
   PubMed Web of Science ®Google Scholar
• Simmet T, Tippler B. Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid. Brain Res. 1990;515(1–2):79–86. doi:10.1016/0006-8993(90)90579-Z
   Web of Science ®Google Scholar
• Theron AJ, Steel HC, Tintinger GR, Gravett CM, Anderson R, Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014;2014:1–16. doi:10.1155/2014/608930
   Web of Science ®Google Scholar
• Zhao R, Shi WZ, Zhang YM, Fang SH, Wei EQ. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol. 2011;63(4):550–557. doi:10.1111/j.2042-7158.2010.01238.x
   Web of Science ®Google Scholar
• Kawai Y, Narita Y, Ogata A, Usui A, Komori K. Therapeutic potential of montelukast, cysteinyl leukotriene receptor 1 antagonist, for aortic aneurysm. Eur J Vasc Endovasc Surg. 2019;58(6):e419. doi:10.1016/j.ejvs.2019.06.1064
   Google Scholar
• Health NI. Livertox: clinical and research information on drug-induced liver injury. US Natl Libr Med. 2017.
   Google Scholar
• Montuschi P, Sala A, Dahlen S-E, Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today. 2007;12(9–10):404–412. doi:10.1016/j.drudis.2007.03.004
   PubMed Web of Science ®Google Scholar
• Saad MA, Abdelsalam RM, Kenawy SA, Attia AS. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Neurochem Res. 2014;40(1):139–150. doi:10.1007/s11064-014-1478-9
   Web of Science ®Google Scholar
• Jadidi-Niaragh F, Mirshafiey A. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology. 2010;59(3):180–189. doi:10.1016/j.neuropharm.2010.05.005
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Huang M-Y, Lee M-S, et al. Effects of montelukast on M2-related cytokine and chemokine in M2 macrophages. J Microbiol Immunol Infect. 2018;51(1):18–26. doi:10.1016/j.jmii.2016.04.005
   Google Scholar
• Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445. doi:10.1038/nature12034
   PubMed Web of Science ®Google Scholar
• Liu D, Ge S, Zhou G, et al. Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits. Cardiovasc Drugs Ther. 2009;23(6):431. doi:10.1007/s10557-009-6211-6
   Web of Science ®Google Scholar
• Bıber N, Toklu HZ, Solakoglu S, et al. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood–brain barrier permeability but does not prevent oedema formation in traumatic brain injury. Brain Inj. 2009;23(6):577–584. doi:10.1080/02699050902926317
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584. doi:10.1038/nm.3407
   PubMed Web of Science ®Google Scholar
• Wang M-L, Huang X-J, Fang S-H, et al. Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression. Biochem Biophys Res Commun. 2006;350(2):399–404. doi:10.1016/j.bbrc.2006.09.057
   Web of Science ®Google Scholar
• Takahashi Y, Imai K, Ikeda H, Kubota Y, Yamazaki E, Susa F. Open study of pranlukast add-on therapy in intractable partial epilepsy. Brain Dev. 2013;35(3):236–244. doi:10.1016/j.braindev.2012.04.001
   PubMed Web of Science ®Google Scholar
• Kobylarek D, Iwanowski P, Lewandowska Z, et al. Advances in the potential biomarkers of epilepsy. Front Neurol. 2019;10.
   Web of Science ®Google Scholar
• Hanisch U-K. Microglia as a source and target of cytokine activities in the brain. In: Microglia in the Regenerating and Degenerating Central Nervous System. Springer; 2002:79–124.
   Google Scholar
• Rothhammer V, Quintana FJ. Control of autoimmune CNS inflammation by astrocytes. In: Seminars in Immunopathology. Vol. 37. Springer; 2015:625–638.
   Google Scholar
• Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46(11):1724–1743. doi:10.1111/j.1528-1167.2005.00298.x
   PubMed Web of Science ®Google Scholar
• Awasthi A, Matsunaga Y, Yamada T. Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides. Exp Neurol. 2005;196(2):282–289. doi:10.1016/j.expneurol.2005.08.001
   Web of Science ®Google Scholar
• Tang -S-S, Hong H, Chen L, et al. Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo. Neurobiol Aging. 2014;35(3):590–599. doi:10.1016/j.neurobiolaging.2013.09.036
   Web of Science ®Google Scholar
• Sima X, Xu J, Li J, Zhong W, You C. Expression of β‑amyloid precursor protein in refractory epilepsy. Mol Med Rep. 2014;9(4):1242–1248. doi:10.3892/mmr.2014.1977
   Web of Science ®Google Scholar
• Costa C, Parnetti L, D’Amelio M, et al. Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link? Neurobiol Aging. 2016;48:161–171. doi:10.1016/j.neurobiolaging.2016.08.025
   PubMed Web of Science ®Google Scholar
• Bales KR, Du Y, Dodel RC, Yan G-M, Hamilton-Byrd E, Paul SM. The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation. Mol Brain Res. 1998;57(1):63–72. doi:10.1016/S0169-328X(98)00066-7
   PubMedGoogle Scholar
• Weiskirchen R. Commentary: montelukast prevents mice against acetaminophen-induced liver injury. Front Pharmacol. 2019;10:1289. doi:10.3389/fphar.2019.01289
   Web of Science ®Google Scholar
• Larner AJ. Epileptic seizures in AD patients. Neuromolecular Med. 2010;12(1):71–77. doi:10.1007/s12017-009-8076-z
   PubMed Web of Science ®Google Scholar
• Elwany NE. Protective effect of montelukast against pentylenetetrazole- induced acute seizures and kindling in mice. ZUMJ. 2015;21(6).
   Google Scholar
• Fleck J, Marafiga JR, Jesse AC, Ribeiro LR, Rambo LM, Mello CF. Montelukast potentiates the anticonvulsant effect of phenobarbital in mice: an isobolographic analysis. Pharmacol Res. 2015;94:34–41. doi:10.1016/j.phrs.2015.02.001
   PubMed Web of Science ®Google Scholar